Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
Holding SPRO?
Track your performance easily
SPRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $1.89
Previous Close$1.33
Volume491.17K
Average Volume (3M)131.04K
Market Cap
$71.89M
Enterprise Value$13.32M
Total Cash (Recent Filing)$63.53M
Total Debt (Recent Filing)$4.96M
Price to Earnings (P/E)4.0
Beta1.24
Next Earnings
Nov 06, 2024EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding54,049,139
10 Day Avg. Volume120,384
30 Day Avg. Volume131,038
Standard Deviation0.27
R-Squared0.01
Alpha-0.00766
Financial Highlights & Ratios
Price to Book (P/B)0.89
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.11
Enterprise Value/Gross Profit0.13
Enterprise Value/Ebitda1.20
Forecast
1Y Price Target
$7.00Price Target Upside426.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Spero Therapeutics News
PremiumCompany Announcements
Spero Therapeutics Restructures Focus on Key R&D Projects
PremiumCompany Announcements
Spero Therapeutics Details Pipeline Progress and Future GoalsBulls Say, Bears Say
Bulls Say
Clinical TrialsSpero's third candidate, SPR206, has received Investigational New Drug (IND) clearance from the FDA to enter a Phase 2 clinical trial in patients with hospital- or ventilator-acquired pneumonia (HAP/VAP).
FDA Approval PotentialThe FDA has indicated that positive and persuasive results from PIVOT-PO, along with data from prior studies, could be sufficient to support approval of tebipenem HBr in complicated urinary tract infections (cUTIs), including pyelonephritis, for a limited use indication.
Pipeline MaturityThe company's pipeline continues to mature, with tebipenem HBr advancing in the PIVOT-PO Phase 3 confirmatory trial and SPR720 being assessed in a Phase 2a trial in treatment-naive and pulmonary disease (NTM-PD) patients.
Bears Say
AnalysisThis analysis has relatively little precedence in NTM, therefore an MCID is difficult to quantify.
EarningsReported net loss of $17.9M.
Financial PerformanceSPRO reported 1Q24 net loss of $12.7M.
---
Ownership Overview
8.46% Insiders
4.38% Mutual Funds
0.98% Other Institutional Investors
82.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $1.00 and its highest was $1.89 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Currently, no data Available
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is 4 days ago.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Aug 05, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.05.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc does not currently pay dividends.
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -$0.5.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 54,049,137 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went down -5.224%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Among the largest hedge funds holding Spero Therapeutics Inc’s share is Royce & Associates LLC. It holds Spero Therapeutics Inc’s shares valued at N/A.
---
Spero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (426.32% Upside)
$7.00 (426.32% Upside)
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.88%
12-Months-Change
Fundamentals
Return on Equity
25.81%
Trailing 12-Months
Asset Growth
51.57%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
---
SPRO Earnings Call
Q2 2024
0:00 / 0:00
---
SPRO Stock 12 Month Forecast
Average Price Target
$7.00
▲(426.32% Upside)
Technical Analysis
Best Analysts Covering SPRO
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-7.20%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -7.20% per trade.
---